18～75歳の喘息患者におけるQGE031とプラセボの有効性および安全性の比較

基本情報

NCT ID

NCT02336425

ステータス

中止

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

10

治験依頼者名

Novartis

概要

This study planned to assess the effect on the reduction in rate of severe asthma exacerbations of different dose levels of QGE031 in asthma patients that are inadequately controlled with inhaled steroid plus beta-2 agonist medication with or without oral steroid. However, this study was terminated due to the efficacy results from an interim analysis (at the end of treatment epoch) of the Phase II study CQGE031B2201 (NCT01716754). Planned data analyses were not performed for this study due to the early termination and the very limited dataset (only 10 participants received study medication of the 440 participants planned).

対象疾患

介入

依頼者（Sponsor）